Lars Björnebo
YOU?
Author Swipe
View article: Can Prostate Cancer Screening Reduce Mortality in Men Aged 75–79 Years? A Protocol for Target-trial Emulation
Can Prostate Cancer Screening Reduce Mortality in Men Aged 75–79 Years? A Protocol for Target-trial Emulation Open
Opportunistic testing using the prostate-specific antigen (PSA) test is common among men aged 75-79 yr. American and European guidelines consider PSA-based screening through joint decision-making if men have at least 10 yr of life expectan…
View article: Detectable prostate‐specific antigen after radiotherapy for clinically localized prostate cancer
Detectable prostate‐specific antigen after radiotherapy for clinically localized prostate cancer Open
Background This study assesses the incidence and timing of undetectable prostate‐specific antigen (PSA) after radiotherapy (RT) ± androgen deprivation therapy (ADT) and its association with prostate cancer mortality. Methods This is a popu…
View article: Epidemiology of High-risk Biochemical Recurrence After Primary Prostate Cancer Treatment
Epidemiology of High-risk Biochemical Recurrence After Primary Prostate Cancer Treatment Open
HR-BCR incidence varies by definition and treatment. The EMBARK criteria identify a smaller subset with the highest PCSM risk. Many patients with BCR never develop HR-BCR. Refining BCR definitions with PSA kinetics and imaging may optimize…
View article: Improving detection and reducing overtreatment of prostate cancer
Improving detection and reducing overtreatment of prostate cancer Open
Prostate cancer is a global health issue being the second most common cancer in men. In Sweden, prostate cancer is the most common cancer in men with one in five Swedish men receiving the diagnosis in their lifetime. The blood biomarker PS…
View article: Prostate cancer incidence and mortality in men exposed to α1-adrenergic receptor antagonists
Prostate cancer incidence and mortality in men exposed to α1-adrenergic receptor antagonists Open
Background α1-Adrenergic receptor antagonists are commonly used to treat benign prostatic hyperplasia. Preclinical studies suggest that they induce cell death and inhibit tumor growth. This study evaluated the risk of prostate cancer death…
View article: Biomarker vs MRI-Enhanced Strategies for Prostate Cancer Screening
Biomarker vs MRI-Enhanced Strategies for Prostate Cancer Screening Open
Importance Prostate cancer guidelines often recommend obtaining magnetic resonance imaging (MRI) before a biopsy, yet MRI access is limited. To date, no randomized clinical trial has compared the use of novel biomarkers for risk estimation…
View article: Biochemical Recurrence and Risk of Mortality Following Radiotherapy or Radical Prostatectomy
Biochemical Recurrence and Risk of Mortality Following Radiotherapy or Radical Prostatectomy Open
Importance Stratifying patients with biochemical recurrence (BCR) after primary treatment for prostate cancer based on the risk of prostate cancer–specific mortality (PCSM) is essential for determining the need for further testing and trea…
View article: Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 2: Subtypes and Divergent Differentiation
Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 2: Subtypes and Divergent Differentiation Open
Following several attempts to achieve a molecular stratification of bladder cancer (BC) over the last decade, a “consensus” classification has been recently developed to provide a common base for the molecular classification of bladder can…
View article: Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 1: General Issues and Marker Expression
Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 1: General Issues and Marker Expression Open
Bladder cancer (BC) is a heterogeneous disease with highly variable clinical and pathological features, and resulting in different outcomes. Such heterogeneity ensues from distinct pathogenetic mechanisms and may consistently affect treatm…
View article: Association of 5α-Reductase Inhibitors With Prostate Cancer Mortality
Association of 5α-Reductase Inhibitors With Prostate Cancer Mortality Open
Importance There is evidence that 5α-reductase inhibitors (5-ARIs), a standard treatment of benign prostate hyperplasia, are associated with a decrease in the incidence of prostate cancer (PCa). However, studies to date have had conflictin…
View article: Predictors of adverse pathology on radical prostatectomy specimen in men initially enrolled in active surveillance for low-risk prostate cancer
Predictors of adverse pathology on radical prostatectomy specimen in men initially enrolled in active surveillance for low-risk prostate cancer Open
Purpose To evaluate clinical variables, including magnetic resonance imaging (MRI) predictive of adverse pathology (AP) at radical prostatectomy (RP) in men initially enrolled in active surveillance (AS). Methods A population-based cohort …